Compare Stocks → You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:IGXTNASDAQ:ITRMNASDAQ:JAGXOTCMKTS:QBIONASDAQ:ZFGN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGXTIntelGenx Technologies$0.17+6.3%$0.16$0.09▼$0.22$29.69M2.4392,761 shs73,325 shsITRMIterum Therapeutics$1.43-2.1%$1.51$0.62▼$2.50$23.50M2.36529,962 shs56,731 shsJAGXJaguar Health$0.18+6.0%$0.09$0.05▼$1.22$48.92M1.3550.93 million shs69.19 million shsQBIOQ BioMed$0.00$0.00$0.00▼$0.02$29K1.7244,432 shs1,123 shsZFGNZafgen$6.38-9.5%$18.47$0.62▼$2.76$239.06M0.27360,199 shs510,629 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGXTIntelGenx Technologies+6.25%-5.74%+3.53%+6.25%-15.00%ITRMIterum Therapeutics-0.69%-11.73%-13.33%-24.74%+20.17%JAGXJaguar Health+7.40%+64.74%+157.04%+74.83%-72.32%QBIOQ BioMed+100.00%+100.00%0.00%-66.67%-98.57%ZFGNZafgen-9.50%-11.63%-25.73%+47.00%+29.67%New crypto project uncovers 2,050% in 65 days (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AITRMIterum Therapeutics0.8538 of 5 stars3.52.00.00.00.60.00.6JAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/AQBIOQ BioMedN/AN/AN/AN/AN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIGXTIntelGenx TechnologiesN/AN/AN/AN/AITRMIterum Therapeutics3.00Buy$6.00319.58% UpsideJAGXJaguar HealthN/AN/AN/AN/AQBIOQ BioMedN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/ACurrent Analyst RatingsLatest ZFGN, ITRM, JAGX, IGXT, and QBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/6/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.002/7/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIGXTIntelGenx Technologies$1.04M28.55N/AN/A($0.07) per share-2.43ITRMIterum TherapeuticsN/AN/AN/AN/A($0.48) per shareN/AJAGXJaguar Health$9.76M5.01N/AN/A$0.07 per share2.53QBIOQ BioMed$280K0.10N/AN/A($0.11) per share0.00ZFGNZafgenN/AN/AN/AN/A$1.35 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/A-955.44%N/A-128.18%N/AITRMIterum Therapeutics-$38.37M-$2.97N/AN/AN/AN/A-664.00%-87.64%5/10/2024 (Estimated)JAGXJaguar Health-$41.30MN/A0.00∞N/A-423.11%-837.11%-80.76%5/20/2024 (Estimated)QBIOQ BioMed-$2.05M-$0.03N/A∞N/AN/AN/AN/A5/26/2024 (Estimated)ZFGNZafgen-$45.41M-$1.07N/A∞N/AN/A-51.34%-34.55%N/ALatest ZFGN, ITRM, JAGX, IGXT, and QBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023IGXTIntelGenx TechnologiesN/A-$0.02-$0.02-$0.03N/A$0.43 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/AQBIOQ BioMedN/AN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIGXTIntelGenx TechnologiesN/A0.410.40ITRMIterum Therapeutics3.631.891.89JAGXJaguar Health6.332.001.34QBIOQ BioMedN/AN/AN/AZFGNZafgen0.266.566.56OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIGXTIntelGenx TechnologiesN/AITRMIterum Therapeutics9.21%JAGXJaguar Health12.04%QBIOQ BioMedN/AZFGNZafgen70.43%Insider OwnershipCompanyInsider OwnershipIGXTIntelGenx Technologies42.05%ITRMIterum Therapeutics5.40%JAGXJaguar Health0.16%QBIOQ BioMed28.20%ZFGNZafgen14.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIGXTIntelGenx Technologies4174.66 million101.21 millionNot OptionableITRMIterum Therapeutics1416.43 million15.54 millionNot OptionableJAGXJaguar Health49276.22 million275.77 millionNo DataQBIOQ BioMed3145.10 million104.18 millionNot OptionableZFGNZafgen3837.47 millionN/ANot OptionableZFGN, ITRM, JAGX, IGXT, and QBIO HeadlinesSourceHeadlineDiagnosing Diabetes: Not So Simplemedscape.com - November 2 at 7:42 AMDo New Weight Loss Meds Mean the End of Bariatric Surgery?medscape.com - October 6 at 8:53 PMPrader-Willi syndromepharmaphorum.com - August 23 at 8:34 PMThe Omnipod 5 System: Trial Results From ENDO 2021medscape.com - August 4 at 8:12 PMBeta Cells From Stem Cells: Nearing a Cure for Type 1 Diabetes?medscape.com - July 5 at 5:09 PMOral Semaglutide Brings GLP-1s to Primary Caremedscape.com - May 20 at 8:49 PMClinical Trials - Different Phases of the trial News, Research and Latest Updatesmedindia.net - May 20 at 3:49 PMObesity Therapeutic Pipeline Analysis, 2023 Updates | Insights into ... - Digital Journalnews.google.com - May 12 at 2:12 PMWeight Loss and Obesity Management Market Insights With ... - Taiwan Newsnews.google.com - May 11 at 3:06 AMGlobal Methionine Aminopeptidase 2 Market Report 2023 by Trend ... - The Northwestern Examinernews.google.com - May 4 at 6:30 PMWeight Loss and Obesity Management Market May See a Big Move ... - Digital Journalnews.google.com - May 2 at 1:13 PMIronwood Pharmaceuticals: A Promising Outlook for Long-Term ... - Best Stocksnews.google.com - May 2 at 8:13 AMThe Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulationmedscape.com - April 29 at 8:09 PMFast Five Quiz: Type 2 Diabetes and Dyslipidemia - Medscape Referencenews.google.com - April 22 at 12:41 AMAnti-Obesity Drugs Market Size, Share, Economic Growth, Emerging ... - Digital Journalnews.google.com - April 20 at 9:32 AMAnti-Obesity Drugs Market Size, Analysis, Share, Research, Business Growth and Forecast to 2031 - openPRnews.google.com - April 14 at 8:21 AMNew ADA Standards: Promoting Healthmedscape.com - April 13 at 7:20 AMNew ADA Standards: Promoting Healthmedscape.com - April 13 at 7:20 AMAnti-Obesity Drugs Market Set to Register a CAGR of 16.10% and ... - GlobeNewswirenews.google.com - April 10 at 12:56 PMGlobal Weight Loss Therapeutics Professional Market 2023 (Exclusive Report) | Future Work Trend by 2030marketwatch.com - April 9 at 10:32 AMAnti-Obesity Drugs Market is expected to rise at A CAGR Of 16.1% during the forecast period 2023 to 2031: Grow - openPRnews.google.com - April 5 at 7:34 AMAnti-Obesity Drugs Market to grow at a CAGR of over 16.1% from 2023 to 2031, reveals Growth Plus Reports - openPRnews.google.com - March 22 at 11:43 AMIndian Anti-Obesity Drug Market 2023 : Projected to Deliver Greater Revenues during the Forecast Period 2028 - openPRnews.google.com - March 1 at 1:17 PMZafgen (ZFGN) Stock Skyrockets on Positive Obesity Drug Resultsthestreet.com - February 26 at 7:51 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsIntelGenx TechnologiesOTCMKTS:IGXTIntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.Iterum TherapeuticsNASDAQ:ITRMIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.Q BioMedOTCMKTS:QBIOQ BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.ZafgenNASDAQ:ZFGNZafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.